Immatics' vaccine prolongs survival in renal cell cancer
This article was originally published in Scrip
Executive Summary
Immatics' lead cancer vaccine IMA901 can prolong survival times in renal cell carcinoma patients whose immune system responds to more than one of its ten constituent tumour-associated peptides (TUMAPs), show Phase I and II data reported in Nature Medicine.